Skip to main content
. Author manuscript; available in PMC: 2021 Aug 11.
Published in final edited form as: Blood Cancer Discov. 2021 Jul;2(4):302–318. doi: 10.1158/2643-3230.BCD-20-0227

Figure 3. Impact of therapy on CAR T-cell activity.

Figure 3.

Treatment prior to leucapheresis, as well as bridging therapy administered to the patient during the production of CAR T-cells, and lymphodepleting chemotherapy prior to CAR T-cell infusion, can have an impact on the anti-tumor effect of CAR T-cells. In addition, in the setting of clinical trials, several agents are administered post CAR T-cell infusion (e.g., IMiDs and CD38-targeting antibodies) to enhance CAR T-cell efficacy or improve CAR T-cell persistence.